Active Biotech Presents New Pre-clinical Data for the 57-57 Project

Active Biotech AB has presented pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation held in Copenhagen. The results strengthen the further clinical development of 57-57 for the treatment of systemic lupus erythematosus, SLE, and show the possibility to reduce the use of steroids.

The new pre-clinical data presented show that 57-57, in an experimental model of the disease SLE, can replace prednisolone, an anti-inflammatory corticosteroid widely used in a broad range of different inflammatory diseases, among them SLE. Several symptoms commonly associated with SLE, such as hematuria and glomerulonephritis could be significantly reduced when combining 57-57 and a lower dose of steroid.

For further information please contact:

Sven Andréasson,

President & CEO

Tel: +46 46 19 20 49

Email: sven.andreasson@activebiotech.com